查看购物车
  • Traditional Chinese
  • English
  • Japanese
梅毒市场－全球及区域分析：依治疗方法、给药途径及地区划分－分析与预测（2026-2036 年）
市场调查报告书
商品编码
2015255

梅毒市场－全球及区域分析：依治疗方法、给药途径及地区划分－分析与预测（2026-2036 年）

Syphilis Market - A Global and Regional Analysis: Treatment Type, Route of Administration, and Regional Analysis - Analysis and Forecast, 2026-2036
出版日期: | 出版商: BIS Research | 英文 109 Pages | 商品交期: 1-5个工作天内

价格

2024 年全球梅毒市场价值为 7.18 亿美元，但预计到 2036 年将达到 12.208 亿美元，2026 年至 2036 年的复合年增长率高达 4.60%。

关键市场统计数据
预测期 2026-2036
2026 年市场规模 7.783亿美元
2036年的预测 12.208亿美元
复合年增长率 4.6%

性行为感染感染率上升、早期诊断和治疗意识增强以及已开发国家和开发中国家筛检计画扩展等因素的推动，全球梅毒市场正经历显着成长。公共卫生工作的加强、诊断检测可及性的改善以及为控制梅毒传播而采取的医疗保健措施的改进，都促进了市场扩张。

此外，诊断技术的进步，包括快速且更准确的临床检测，提高了梅毒的检出率，并实现了及时的临床干预。对孕产妇和产前筛检的日益重视，以及对感染疾病控制和性健康计画的投入增加，也对市场产生了正面影响。随着对有效诊断、治疗和预防策略的需求持续增长，预计全球梅毒市场将在预测期内保持稳定成长。

市场概览

全球梅毒市场正稳步成长，预计未来将继续扩张，这主要得益于公众意识的提高、诊断方法的进步以及公共卫生部门为遏制性行为感染（STI）蔓延而采取的措施。市场成长的主要驱动因素是梅毒盛行率的上升，尤其是在高风险族群中，以及人们越来越重视早期诊断和治疗，以遏制感染的传播并预防併发症，包括先天性梅毒。诊断检测的普及，包括快速就地检验和更先进的临床检测，在推动市场扩张方面发挥重要作用。此外，政府主导的旨在意识提升的各项措施和医疗保健计划的增加，以及对更有效治疗方法日益增长的需求，都进一步推动了市场的成长。

对产业的影响

受对更先进的诊断方法、治疗方法和预防措施的需求不断增长的推动，全球梅毒市场正经历显着增长。这种成长对包括医疗保健、製药和公共卫生在内的多个行业产生了重大影响。在医疗产业，梅毒病例的增加促使人们更加重视早期发现和有效管理，从而加速了快速检测套组等先进诊断工具和改进的临床实验室方法的应用。

在製药领域，人们对开发治疗梅毒的新治疗方法和新选择，以及治疗常伴随梅毒发生的合併感染疾病的药物越来越感兴趣。这刺激了研发领域的创新和投资，从而促进了製药业的成长。

公共卫生领域也受到了显着影响，各国政府和非政府组织（NGO）正加强透过宣传宣传活动、疫苗接种计划和产前筛检来预防先天性梅毒，从而遏制梅毒的蔓延。这些努力推动了对更便利的检测和治疗方法的需求成长，重塑了市场动态，并促进了该行业的进一步发展。

这些领域之间的协同作用正在推动对梅毒采取更强有力、更全面的应对措施，最终改善全球健康状况，并推动市场持续成长。

市场区隔:

细分 1：依给药途径

  • 注射药物
  • 口服药物

在梅毒市场（按给药途径划分），注射剂药物预计将占据主导地位。

就给药途径而言，注射剂预计将主导梅毒市场。这是因为注射用抗生素，特别是青霉素，在治疗梅毒感染疾病已被证实有效。青霉素仍然是梅毒的标准治疗方法，尤其是在晚期梅毒（如第三期梅毒和先天性梅毒）。注射用青霉素因其生物利用度高，且能快速可靠地发挥治疗作用而备受青睐。

在临床实务中，注射以青霉素特别受欢迎，因为它能确保剂量稳定可控，这对于有效治疗梅毒和预防併发症至关重要。肌注青霉素（通常为芐星青霉素G）是治疗方法不同阶段梅毒的建议方法。这种给药途径能使抗生素在体内维持较长时间的活性，有助于清除引起梅毒的梅毒螺旋体。

鑑于注射用抗生素仍然是标准治疗方法，而且全球梅毒病例数量不断增加，在既定的临床指南和注射用抗生素的有效性的支持下，注射用抗生素领域预计将保持其市场主导地位。

分割方式 2：依治疗方法

  • 青霉素类药物治疗
  • 其他抗生素

预计青霉素类药物将成为梅毒治疗市场的主导疗法（按治疗方法）。

青霉素已被证实对治疗感染疾病有效，并且仍然是梅毒治疗的黄金标准；因此，基于青霉素的治疗方法预计将主导梅毒市场。青霉素，特别是芐星青霉素G，广泛用于治疗各阶段的梅毒，从早期和二期到潜伏期和第三期。它对致病菌梅毒螺旋体（Treponema pallidum）具有极高的疗效，几十年来一直是梅毒治疗的基础，因此被推荐为第一线药物。

青霉素的优越性得到了长期临床成功以及包括世界卫生组织（WHO）和美国疾病管制与预防中心（CDC）在内的国际卫生组织制定的指南的支持。这些组织推荐青霉素作为梅毒的第一线治疗药物。注射用青霉素可在体内长期停留，为治疗梅毒提供了可靠的单剂量解决方案。

由于青霉素类治疗方法易于取得、价格实惠且具有强大的临床证据，因此它仍将是治疗梅毒最常用和首选的药物，并且在可预见的未来很可能继续保持其在市场上的主导地位。

细分3：按地区

  • 北美洲
    • 我们
    • 加拿大
  • 北美洲，美国
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚洲及大洋洲
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 亚洲和大洋洲的其他地区
  • 其他地区
    • 拉丁美洲和加勒比海地区
    • 北非和中东

区域脑膜炎球菌市场：预计亚洲和大洋洲将占据主导地位

由于性行为感染​​感染（STI）发病率上升、公众意识增强以及医疗基础设施改善，亚太地区预计将成为梅毒市场的主要驱动力。这两个地区人口密度高，医疗服务覆盖范围广，因此都在加强公共卫生力度，透过早期诊断、治疗和预防计画来对抗梅毒。

在亚洲，由于都市化、性行为改变以及性健康意识增强等因素，中国、印度和日本等国的梅毒病例正在增加。这些国家正透过政府计画、筛检计画和宣传宣传活动，加强预防性性行为感染感染（STI），促进了市场成长。医疗服务的扩展，尤其是在遍远地区，进一步推动了对诊断检测和治疗的需求。

在大洋洲，特别是澳洲和纽西兰，公共卫生部门正强调梅毒筛检的重要性，尤其要重视孕妇的筛检，以预防先天性梅毒。此外，完善的医疗保健体係以及性健康意识的提高，正在扩大梅毒检测和治疗的覆盖范围。

随着人们对梅毒的认识不断提高，以及这些地区医疗保健服务的改善，预计亚洲和大洋洲将继续保持其在全球梅毒市场的主导地位，这主要得益于对有效诊断和治疗方法的需求不断增长。

梅毒市场近期趋势

  • 截至 2026 年 2 月，Aurobindo Pharma Limited 预计透过扩大其位于安得拉邦的综合工厂的产能，将在 12 个月内实现青霉素 G (Pen-G) 约 10,000 公吨的产量。
  • 2026 年 1 月，印度对青霉素及其主要衍生物（青霉素 G、6-氨基青霉素和三水阿莫西林）实施了为期一年的最低进口价格 (MIP)，以遏制低价进口，特别是来自中国的进口，并保护像 Aurobindo Pharma Limited 这样的国内製造商。
  • 2025 年 3 月，山德士集团股份公司在奥地利昆德尔开设了一家新的抗生素生产厂，耗资 5,000 万欧元，使产量提高了约 20%（每年 2.4 亿包），并能够额外生产 10 亿片青霉素片，以满足不断增长的全球需求。

需求——驱动因素、挑战与机会

市场驱动因素

梅毒发病率上升：全球梅毒的捲土重来反映出预防、早期发现和持续公共卫生投入方面的系统性缺陷，即使在高所得国家也是如此。男男性行为者（MSM）、免疫力缺乏病毒感染者和孕妇受到的影响尤其严重，这表明结构性和行为性脆弱性依然存在；而先天性病例的增加则表明孕产妇筛检和治疗项目存在重大缺陷。保险套使用率下降、网路性行为增加、社会歧视以及医疗保健服务取得的不平等现象表明，目前的措施不足以应对疫情。如果没有针对特定族群的综合干预措施和加强监测系统，那么到2035年梅毒发病率将持续居高不下的预测很可能成为现实。

市场挑战

芐星青霉素G（梅毒一线治疗金标准）的反覆供不应求严重限制了市场成长。间歇性的供应供不应求、生产集中以及低利润率的经济结构限制了该药物的稳定供应，尤其对孕妇等高危险群而言更是如此。这种不稳定性迫使人们依赖临床疗效有限的替代疗法，降低了治疗指引的依从性，并影响了整体治疗量。此外，采购的不确定性和订单积压也削弱了生产商和公共卫生项目的收入可预测性。如果没有供应链多元化和生产奖励，芐星青霉素G的供不应求将继续成为梅毒市场的结构性限制。

市场机会

梅毒诊断检测的普及与推广—在快速、即时检测 (POC)、居家检测和自动化检测解决方案创新推动下，梅毒市场正经历强劲成长。获得 FDA已通过核准的即时检测和非处方检测产品，例如梅毒健康检查 (Syphilis Health Check) 和“First to Know Syphilis Test”，正在扩大检测范围，减少社会歧视，并实现当日启动治疗。 HIV-梅毒联合检测和自动化梅毒螺旋体免疫检测正在简化高流量、高风险环境下的工作流程，提高效率和诊断准确性。公共卫生倡议、复检通讯协定以及与更广泛的性行为感染(STI)筛检计画的整合进一步推动了市场扩张。分析师认为，这些趋势将形成永续的成长轨迹，分散式检查检测和检查室检测都将推动长期市场渗透和商机。

这份报告将为贵组织带来哪些价值？

产品与创新策略－全球梅毒市场细分为多个关键部分，包括给药途径、治疗方法和区域市场。透过了解哪些细分市场占据最大的市场份额以及哪些细分市场具有成长潜力，本报告为旨在创新产品和扩展产品组合的企业提供了宝贵的见解。

成长和行销策略—策略伙伴关係、联盟和业务扩张预计将在梅毒市场的成长中发挥核心作用。

竞争策略：梅毒市场竞争异常激烈，许多老字型大小企业提供各种诊断方案和青霉素类药物疗法。製药公司致力于提供有效的治疗方法，而诊断公司则致力于开发更快、更准确的检测方法。公共卫生组织也透过宣传宣传活动和筛检计画做出贡献。随着对更精准诊断和治疗的需求不断增长，市场参与者正致力于提升服务水准并扩大业务范围，以保持竞争力。

调查方法

市场设计与检验的关键考量与假设

  • 为了估算全球市场规模，涵盖的期间为 2024 年至 2036 年，其中 2024 年为基准年，2026 年至 2036 年为预测期。
  • 本报告的研究范围是基于来自医疗保健、製药、诊断、公共卫生和监管机构等行业专家的见解。报告对梅毒市场进行了详细分析，涵盖趋势、成长要素、竞争格局和新兴机会，同时检验了诊断和治疗方法的进步等因素。
  • 预计梅毒市场未来将出现显着成长，这项预测是基于对现有解决方案的历史数据分析得出的。
  • 每家公司的企业获利均根据其2024年年度报告计算。对于私人公司，企业获利估算则来自一手调查数据、资金筹措历史、市场合作关係和业务表现。
  • 本报告基于现有的梅毒相关产品和服务，对市场进行了分析。报告识别并概述了该领域提供重要产品和服务的主要企业。

主要市场参与者和竞争格局概述

本报告中介绍的公司简介是根据对每家公司的业务范围、产品系列和市场渗透率的分析而选择的。

该市场的主要企业包括以下几家：

  • AdvaCare Pharma
  • Centurion Healthcare
  • Cipla
  • Eurofarma
  • Fresenius Kabi AG
  • Jolly Healthcare
  • Laboratoires Delbert
  • Pfizer Inc.
  • Sandoz Group AG
  • Teva Pharmaceuticals

目录

执行摘要

第一章：全球梅毒市场：产业展望

  • 市场概览
    • 市场概览
  • 流行病学分析
  • 市场趋势
    • 影响分析
  • 监理情势
    • 美国法规结构
    • 欧洲的法规结构
    • 亚洲和大洋洲的法规结构
  • 管道分析
  • 市场动态
    • 驱动因素、挑战和机会：当前和未来影响评估
    • 市场驱动因素
    • 市场挑战
    • 市场机会

第二章：全球梅毒市场（依治疗方法划分），百万美元，2024-2036年

  • 青霉素类药物治疗
  • 其他抗生素

第三章：全球梅毒市场（依给药途径划分），百万美元，2024-2036年

  • 注射药物
  • 口服药物

第四章：全球梅毒市场（按地区划分），百万美元，2024-2036年

  • 区域概况
  • 北美洲
  • 欧洲
  • 亚洲及大洋洲
  • 其他地区

第五章：竞争标竿分析与公司概况

  • 关键策略与趋势（2021年1月至2026年2月）
  • 主要发展分析（依公司划分）
  • 公司简介
    • AdvaCare Pharma
    • Centurion Healthcare
    • Cipla
    • Eurofarma
    • Fresenius Kabi AG
    • Jolly Healthcare
    • Laboratoires Delbert
    • Pfizer Inc.
    • Sandoz Group AG
    • Teva Pharmaceuticals

第六章：调查方法

Product Code: BHL3100SA

This report can be delivered within 1 working day.

Introduction of the Syphilis Market

The global syphilis market, initially valued at $718.0 million in 2024, is projected to grow substantially, reaching $1,220.8 million by 2036, reflecting a remarkable compound annual growth rate (CAGR) of 4.60% from 2026 to 2036.

KEY MARKET STATISTICS
Forecast Period2026 - 2036
2026 Evaluation$778.3 Million
2036 Forecast$1,220.8 Million
CAGR4.6%

The global syphilis market is experiencing significant growth, driven by the rising incidence of sexually transmitted infections, increasing awareness regarding early diagnosis and treatment, and the expanding availability of screening programs across both developed and developing regions. Growing public health initiatives, improved access to diagnostic testing, and stronger efforts by healthcare organizations to control the spread of syphilis are contributing to market expansion.

In addition, advancements in diagnostic technologies, including rapid testing methods and more accurate laboratory-based assays, are improving detection rates and supporting timely clinical intervention. The market is also benefiting from greater emphasis on maternal and prenatal screening to prevent congenital syphilis, alongside increasing investments in infectious disease management and sexual health programs. As demand for effective diagnosis, treatment, and prevention strategies continues to rise, the global syphilis market is expected to maintain steady growth over the forecast period.

Market Introduction

The global syphilis market has experienced steady growth and is projected to continue expanding, driven by increasing awareness, advancements in diagnostic methods, and growing public health efforts to control the spread of sexually transmitted infections (STIs). The market growth is primarily fuelled by rising syphilis incidence rates, particularly in high-risk populations, and an increasing focus on early diagnosis and treatment to reduce transmission and prevent complications, including congenital syphilis. Enhanced access to diagnostic tests, including rapid point-of-care tests and improved laboratory diagnostics, is playing a key role in driving market expansion. Additionally, the rise of government initiatives and healthcare programs aimed at improving sexual health awareness, alongside the growing demand for more effective treatment options, further supports the market's growth trajectory.

Industrial Impact

The global syphilis market has witnessed significant growth, driven by the increasing demand for improved diagnostics, treatments, and preventive measures. This growth is having a substantial impact across various industries, including healthcare, pharmaceuticals, and public health. In the healthcare industry, the rise in syphilis cases has led to greater emphasis on early detection and effective management, encouraging the adoption of advanced diagnostic tools like rapid testing kits and improved laboratory assays.

In the pharmaceutical sector, there has been a growing focus on developing new treatments and therapeutic options for syphilis, as well as medications to address co-infections often associated with the disease. This has spurred innovation and investment in research and development, contributing to the growth of the pharmaceutical industry.

The public health sector is also significantly impacted, with governments and non-governmental organizations ramping up efforts to combat syphilis through awareness campaigns, vaccination programs, and prenatal screenings to prevent congenital syphilis. These efforts are increasing demand for more accessible testing and treatment options, thus shaping the market dynamics and driving further industry advancements.

The synergy between these sectors is fostering a more robust and integrated response to syphilis, ultimately enhancing global health outcomes while driving continued growth in the market.

Market Segmentation:

Segmentation 1: By Route of Administration

  • Injectables
  • Oral Medications

Injectables Segment to Dominate the Syphilis Market (by Route of Administration)

The injectables segment is expected to dominate the syphilis market by route of administration, driven by the proven efficacy of injectable antibiotics, particularly penicillin, in treating syphilis infections. Penicillin remains the standard treatment for syphilis, especially in its later stages, such as tertiary syphilis or congenital syphilis. The injectable form of penicillin is preferred due to its high bioavailability and ability to provide a rapid and reliable therapeutic effect.

Injectables are particularly favoured in clinical settings due to their ability to ensure consistent and controlled dosing, which is essential for effectively treating syphilis and preventing complications. The intramuscular (IM) administration of penicillin, commonly in the form of Benzathine penicillin G, is the recommended treatment for syphilis across various stages of infection. This method of administration ensures that the antibiotic remains active in the body for a prolonged period, helping to eliminate the syphilis-causing bacterium, Treponema pallidum.

As the standard treatment remains an injectable, and due to the growing number of syphilis cases globally, the injectables segment is anticipated to continue its dominance in the market, supported by the established clinical guidelines and the proven effectiveness of injectable antibiotics.

Segmentation 2: By Treatment Type

  • Penicillin-based Treatment
  • Other Antibiotics

Penicillin-based Treatment to Dominate the Syphilis Market (by Treatment Type)

Penicillin-based treatment is expected to dominate the syphilis market by treatment type, as penicillin remains the gold standard for syphilis therapy due to its proven effectiveness in curing the infection. Penicillin, particularly Benzathine penicillin G, is widely used to treat syphilis at all stages, from primary and secondary to latent and tertiary syphilis. It is the preferred treatment because it is highly effective against the causative bacterium, Treponema pallidum, and has been the cornerstone of syphilis management for decades.

Penicillin's dominance is supported by its long history of clinical success and established guidelines from global health organizations, including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), which recommend it as the first-line treatment for syphilis. The injectable form of penicillin ensures that the drug remains in the system for a prolonged period, offering a reliable, single-dose solution for treating syphilis.

Due to its widespread availability, affordability, and strong clinical evidence, penicillin-based treatments will continue to be the most prescribed and preferred option for syphilis treatment, maintaining their dominant position in the market for the foreseeable future.

Segmentation 3: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia and Oceania
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest-of-Asia and Oceania
  • Rest-of-the-World
    • Latin America and Caribbean
    • North Africa and Middle East

Asia and Oceania to Dominate the Syphilis Market (by Region)

Asia and Oceania are expected to dominate the syphilis market due to the rising incidence of sexually transmitted infections (STIs), increasing awareness, and improving healthcare infrastructure in the region. With high population densities and expanding access to healthcare, both regions are experiencing significant public health efforts to combat syphilis through early diagnosis, treatment, and prevention programs.

In Asia, countries such as China, India, and Japan are witnessing an uptick in syphilis cases, driven by factors such as urbanization, changing sexual behaviors, and a growing focus on sexual health. These countries are also increasing their efforts in STI prevention through government programs, screening initiatives, and awareness campaigns, which are contributing to market growth. The expansion of healthcare services, especially in rural areas, is further driving demand for diagnostic tests and treatments.

In Oceania, particularly in Australia and New Zealand, public health authorities are emphasizing the importance of syphilis screening, particularly for pregnant women, to prevent congenital syphilis. Additionally, the implementation of robust healthcare systems, along with a growing focus on sexual health, is promoting syphilis testing and treatment availability.

As awareness and healthcare access continue to improve in these regions, Asia and Oceania are set to maintain a dominant position in the global syphilis market, driven by increased demand for effective diagnosis and treatment options.

Recent Developments in the Syphilis Market

  • As of February 2026, Aurobindo Pharma Limited expects Penicillin-G (Pen-G) production to reach ~10,000 metric tonnes within 12 months as it scales output from its integrated Andhra Pradesh facility.
  • In January 2026, India imposed a one-year minimum import price (MIP) on penicillin and key derivatives (Pen-G, 6-APA, amoxicillin trihydrate) to curb low-cost imports, especially from China, and protect domestic manufacturers such as Aurobindo Pharma Limited.
  • In March 2025, Sandoz Group AG opened a new €50 million antibiotic production facility in Kundl, Austria, boosting output by ~20% (to 240 million packages/year) and enabling production of one billion additional penicillin tablets to meet rising global demand.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Rising Incidence of Syphilis: The global resurgence of syphilis reflects systemic gaps in prevention, early detection, and sustained public health investment, even in high-income settings. Disproportionate impacts among MSM, people living with human immunodeficiency virus (HIV), and pregnant women indicate persistent structural and behavioural vulnerabilities, while rising congenital cases signal critical failures in maternal screening and treatment programs. The convergence of reduced condom use, digital sexual networking, stigma, and uneven healthcare access suggests that current control strategies are insufficiently adaptive. Without integrated, population-specific interventions and strengthened surveillance, projections of sustained high incidence through 2035 are likely to materialize.

Market Challenges

Recurrent Shortage of the Primary Treatment, Benzathine Penicillin G: The recurrent shortage of benzathine penicillin G (BPG), the gold-standard first-line therapy for syphilis, is significantly constraining market growth. Persistent supply disruptions, manufacturing concentration, and low-margin economics limit consistent drug availability, particularly for high-risk groups such as pregnant women. This instability forces reliance on alternative regimens with clinical limitations, reducing adherence to treatment guidelines and affecting overall treatment volumes. Additionally, procurement uncertainty and backorders weaken revenue predictability for manufacturers and public health programs. Without supply chain diversification and production incentives, BPG shortages will continue to act as a structural restraint on the syphilis market.

Market Opportunities

Expansion of Advanced and Accessible Syphilis Diagnostic Testing: The syphilis market is experiencing robust growth driven by innovations in rapid, point-of-care, at-home, and automated testing solutions. FDA-cleared POC and OTC tests, such as the Syphilis Health Check and First to Know Syphilis Test, are expanding access, reducing stigma, and enabling same-day treatment initiation. Dual HIV-syphilis assays and automated treponemal immunoassays are streamlining workflows in high-volume and high-risk settings, improving efficiency and diagnostic accuracy. Market expansion is further supported by public health initiatives, repeat testing protocols, and integration into broader STI screening programs. Analysts view these trends as creating a sustainable growth trajectory, with both decentralized and lab-based testing driving long-term adoption and revenue opportunities.

How can this report add value to an organization?

Product/Innovation Strategy: The global syphilis market has been divided into several key segments, including route of administration, treatment type, and regional markets. By understanding which segments hold the largest share and which ones show potential for growth, this report offers invaluable insights for organizations looking to innovate and expand their product offerings.

Growth/Marketing Strategy: Strategic partnerships, collaborations, and business expansions are anticipated to be central to the growth of the syphilis market.

Competitive Strategy: The syphilis market is highly competitive, with numerous well-established players offering a range of diagnostic solutions and penicillin-based treatments. Pharmaceutical companies focus on providing effective therapies, while diagnostic firms are innovating with faster, more accurate testing methods. Public health organizations also contribute through awareness campaigns and screening programs. As demand for better diagnosis and treatment increases, market players are focusing on enhancing their offerings and expanding their reach to stay competitive.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Years from 2024 to 2036 have been considered for the global market size estimation, 2024 has been considered as the base year, and 2026 to 2036 as the forecast period.
  • The scope of the report is based on insights from industry experts across healthcare, pharmaceuticals, diagnostics, public health, and regulatory bodies. It offers a detailed analysis of the syphilis market, covering trends, growth drivers, competition, and emerging opportunities, while examining factors like advancements in diagnostics and treatment options.
  • The market for syphilis is anticipated to grow substantially in the future, with projections based on historical analysis of available solutions.
  • Revenues from companies have been sourced from their annual reports for FY2024. For private companies, revenue estimates are derived from primary research inputs, funding history, market collaborations, and operational performance.
  • The market has been mapped based on the existing syphilis products and services. Key companies with significant offerings in this field have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts in syphilis, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • validation and triangulation of all the numbers and graphs
  • validation of report segmentations and key qualitative findings
  • understanding the competitive landscape and business model
  • current and proposed production values of a product by market players
  • validation of the numbers of different segments of the market in focus
  • percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investors' presentations of the leading market players
  • Company websites and a detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • segmentations and percentage shares
  • data for market value
  • key industry trends of the top players in the market
  • qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • AdvaCare Pharma
  • Centurion Healthcare
  • Cipla
  • Eurofarma
  • Fresenius Kabi AG
  • Jolly Healthcare
  • Laboratoires Delbert
  • Pfizer Inc.
  • Sandoz Group AG
  • Teva Pharmaceuticals

Table of Contents

Executive Summary

Scope and Definition

1 Global Syphilis Market: Industry Outlook

  • 1.1 Market Overview
    • 1.1.1 Market Overview
  • 1.2 Epidemiological Analysis
  • 1.3 Market Trends
    • 1.3.1 Impact Analysis
      • 1.3.1.1 Integrated Antenatal Infection Panels (HIV-HBV-Syphilis) Becoming a Standard Procurement and Scale-Up Model
      • 1.3.1.2 Self-Testing and Decentralized Testing Expanding the Addressable Treatment Population
  • 1.4 Regulatory Landscape
    • 1.4.1 Regulatory Framework in the U.S.
    • 1.4.2 Regulatory Framework in Europe
    • 1.4.3 Regulatory Framework in Asia and Oceania
      • 1.4.3.1 Regulatory Framework in China
      • 1.4.3.2 Regulatory Framework in Japan
      • 1.4.3.3 Regulatory Framework in Australia
  • 1.5 Pipeline Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
    • 1.6.2 Market Drivers
      • 1.6.2.1 Rising Incidence of Syphilis
      • 1.6.2.2 Increased Screening Initiatives
    • 1.6.3 Market Challenges
      • 1.6.3.1 Recurrent Shortage of the Primary Treatment, Benzathine Penicillin G
      • 1.6.3.2 Limited Availability of Alternative Therapies for Syphilis
    • 1.6.4 Market Opportunities
      • 1.6.4.1 Expansion of Advanced and Accessible Syphilis Diagnostic Testing

2 Global Syphilis Market (by Treatment Type), $Million, 2024-2036

  • 2.1 Penicillin-based Treatment
    • 2.1.1 Overview
    • 2.1.2 Market Sizing and Forecast
  • 2.2 Other Antibiotics
    • 2.2.1 Overview
    • 2.2.2 Market Sizing and Forecast

3 Global Syphilis Market (by Route of Administration), $Million, 2024-2036

  • 3.1 Injectables
    • 3.1.1 Overview
    • 3.1.2 Market Sizing and Forecast
  • 3.2 Oral Medications
    • 3.2.1 Overview
    • 3.2.2 Market Sizing and Forecast

4 Global Syphilis Market (by Region), $Million, 2024-2036

  • 4.1 Regional Summary
  • 4.2 North America
    • 4.2.1 Regional Overview
    • 4.2.2 Driving Factors for Market Growth
    • 4.2.3 Factors Challenging the Market
    • 4.2.4 Analyst View
    • 4.2.5 Market Sizing and Forecast
      • 4.2.5.1 North America Syphilis Market, by Country
        • 4.2.5.1.1 U.S.
        • 4.2.5.1.2 Canada
  • 4.3 Europe
    • 4.3.1 Regional Overview
    • 4.3.2 Driving Factors for Market Growth
    • 4.3.3 Factors Challenging the Market
    • 4.3.4 Analyst View
    • 4.3.5 Market Sizing and Forecast
      • 4.3.5.1 Europe Syphilis Market, by Country
        • 4.3.5.1.1 U.K.
        • 4.3.5.1.2 Germany
        • 4.3.5.1.3 France
        • 4.3.5.1.4 Italy
        • 4.3.5.1.5 Spain
        • 4.3.5.1.6 Rest-of-Europe
  • 4.4 Asia and Oceania
    • 4.4.1 Regional Overview
    • 4.4.2 Driving Factors for Market Growth
    • 4.4.3 Factors Challenging the Market
    • 4.4.4 Analyst View
    • 4.4.5 Market Sizing and Forecast
      • 4.4.5.1 Asia and Oceania Syphilis Market, by Country
        • 4.4.5.1.1 China
        • 4.4.5.1.2 Japan
        • 4.4.5.1.3 India
        • 4.4.5.1.4 South Korea
        • 4.4.5.1.5 Australia
        • 4.4.5.1.6 Rest-of-Asia and Oceania
  • 4.5 Rest-of-the-World
    • 4.5.1 Regional Overview
    • 4.5.2 Driving Factors for Market Growth
    • 4.5.3 Factors Challenging the Market
    • 4.5.4 Analyst View
    • 4.5.5 Market Sizing and Forecast
      • 4.5.5.1 Rest-of-the-World Syphilis Market, by Country
        • 4.5.5.1.1 Latin America and Caribbean
        • 4.5.5.1.2 North Africa and Middle East

5 Competitive Benchmarking and Company Profiles

  • 5.1 Key Strategies and Developments, January 2021-February 2026
  • 5.2 Key Developments Analysis (by Company)
  • 5.3 Company Profiles
    • 5.3.1 AdvaCare Pharma
      • 5.3.1.1 Overview
      • 5.3.1.2 Top Products/Product Portfolio
      • 5.3.1.3 Top Competitors
      • 5.3.1.4 Target Customers
      • 5.3.1.5 Key Personnel
      • 5.3.1.6 Analyst View
    • 5.3.2 Centurion Healthcare
      • 5.3.2.1 Overview
      • 5.3.2.2 Top Products/Product Portfolio
      • 5.3.2.3 Top Competitors
      • 5.3.2.4 Target Customers
      • 5.3.2.5 Key Personnel
      • 5.3.2.6 Analyst View
    • 5.3.3 Cipla
      • 5.3.3.1 Overview
      • 5.3.3.2 Top Products/Product Portfolio
      • 5.3.3.3 Top Competitors
      • 5.3.3.4 Target Customers
      • 5.3.3.5 Key Personnel
      • 5.3.3.6 Analyst View
    • 5.3.4 Eurofarma
      • 5.3.4.1 Overview
      • 5.3.4.2 Top Products/Product Portfolio
      • 5.3.4.3 Top Competitors
      • 5.3.4.4 Target Customers
      • 5.3.4.5 Key Personnel
      • 5.3.4.6 Analyst View
    • 5.3.5 Fresenius Kabi AG
      • 5.3.5.1 Overview
      • 5.3.5.2 Top Products/Product Portfolio
      • 5.3.5.3 Top Competitors
      • 5.3.5.4 Target Customers
      • 5.3.5.5 Key Personnel
      • 5.3.5.6 Analyst View
    • 5.3.6 Jolly Healthcare
      • 5.3.6.1 Overview
      • 5.3.6.2 Top Products/Product Portfolio
      • 5.3.6.3 Top Competitors
      • 5.3.6.4 Target Customers
      • 5.3.6.5 Key Personnel
      • 5.3.6.6 Analyst View
    • 5.3.7 Laboratoires Delbert
      • 5.3.7.1 Overview
      • 5.3.7.2 Top Products/Product Portfolio
      • 5.3.7.3 Top Competitors
      • 5.3.7.4 Target Customers
      • 5.3.7.5 Key Personnel
      • 5.3.7.6 Analyst View
    • 5.3.8 Pfizer Inc.
      • 5.3.8.1 Overview
      • 5.3.8.2 Top Products/Product Portfolio
      • 5.3.8.3 Top Competitors
      • 5.3.8.4 Target Customers
      • 5.3.8.5 Key Personnel
      • 5.3.8.6 Analyst View
    • 5.3.9 Sandoz Group AG
      • 5.3.9.1 Overview
      • 5.3.9.2 Top Products/Product Portfolio
      • 5.3.9.3 Top Competitors
      • 5.3.9.4 Target Customers
      • 5.3.9.5 Key Personnel
      • 5.3.9.6 Analyst View
    • 5.3.10 Teva Pharmaceuticals
      • 5.3.10.1 Overview
      • 5.3.10.2 Top Products/Product Portfolio
      • 5.3.10.3 Top Competitors
      • 5.3.10.4 Target Customers
      • 5.3.10.5 Key Personnel
      • 5.3.10.6 Analyst View

6 Research Methodology

  • 6.1 Data Sources
    • 6.1.1 Primary Data Sources
    • 6.1.2 Secondary Data Sources
    • 6.1.3 Data Triangulation
  • 6.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Syphilis Market (by Scenario), $Million, 2024, 2026, and 2036
  • Figure 2: Global Syphilis Market, 2024 and 2036
  • Figure 3: Global Syphilis Market (by Country), $Million, 2024
  • Figure 4: Global Syphilis Market, $Million, 2024 and 2036
  • Figure 5: Global Syphilis Market (by Treatment Type), $Million, 2024, 2029, and 2036
  • Figure 6: Global Syphilis Market (by Route of Administration), $Million, 2024, 2029, and 2036
  • Figure 7: Global Syphilis Market (by Treatment Type), $Million, 2025, 2030, and 2036
  • Figure 8: Global Syphilis Market (Penicillin-based Treatment), $Million, 2024-2036
  • Figure 9: Global Syphilis Market (Other Antibiotics), $Million, 2024-2036
  • Figure 10: Global Syphilis Market (by Route of Administration), $Million, 2025, 2030, and 2036
  • Figure 11: Global Syphilis Market (Injectables), $Million, 2024-2036
  • Figure 12: Global Syphilis Market (Oral Medications), $Million, 2024-2036
  • Figure 13: North America Syphilis Market, $Million, 2024-2036
  • Figure 14: U.S. Syphilis Market, $Million, 2024-2036
  • Figure 15: Canada Syphilis Market, $Million, 2024-2036
  • Figure 16: Europe Syphilis Market, $Million, 2024-2036
  • Figure 17: U.K. Syphilis Market, $Million, 2024-2036
  • Figure 18: Germany Syphilis Market, $Million, 2024-2036
  • Figure 19: France Syphilis Market, $Million, 2024-2036
  • Figure 20: Italy Syphilis Market, $Million, 2024-2036
  • Figure 21: Spain Syphilis Market, $Million, 2024-2036
  • Figure 22: Rest-of-Europe Syphilis Market, $Million, 2024-2036
  • Figure 23: Asia and Oceania Syphilis Market, $Million, 2024-2036
  • Figure 24: China Syphilis Market, $Million, 2024-2036
  • Figure 25: Japan Syphilis Market, $Million, 2024-2036
  • Figure 26: India Syphilis Market, $Million, 2024-2036
  • Figure 27: South Korea Syphilis Market, $Million, 2024-2036
  • Figure 28: Australia Syphilis Market, $Million, 2024-2036
  • Figure 29: Rest-of-Asia and Oceania Syphilis Market, $Million, 2024-2036
  • Figure 30: Rest-of-the-World Syphilis Market, $Million, 2024-2036
  • Figure 31: Latin America and Caribbean Syphilis Market, $Million, 2024-2036
  • Figure 32: North Africa and Middle East Syphilis Market, $Million, 2024-2036
  • Figure 33: Key Strategies and Developments, January 2021-February 2026
  • Figure 34: Data Triangulation
  • Figure 35: Top-Down and Bottom-Up Approach
  • Figure 36: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Epidemiological Analysis of Incidence of Syphilis, 2019-2023
  • Table 3: Pipeline Analysis
  • Table 4: Global Syphilis Market (by Region), $Million, 2024-2036
  • Table 5: North America Syphilis Market (by Country), $Million, 2024-2036
  • Table 6: Europe Syphilis Market (by Country), $Million, 2024-2036
  • Table 7: Asia and Oceania Syphilis Market (by Country), $Million, 2024-2036
  • Table 8: Rest-of-the-World Syphilis Market (by Country), $Million, 2024-2036
  • Table 9: Major Key Strategies, January 2021-February 2026